Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Rebecca Shatsky

Breast Oncology · UCSD

View

Dr. Robert Bast

Breast Oncology · MD Anderson Cancer Center

View

Dr. Sara Tolaney

Breast Oncology · Dana-Farber Cancer Institute

View

Dr. Jason Mouabbi

Breast Oncology · MD Anderson Cancer Center

View

Dr. Matthew Kurian

Breast Oncology · St Elizabeth Healthcare

View

Dr. Sarah Premji

Breast Oncology

View

Dr. Roberto Leon-Ferre

Breast Oncology · Mayo Clinic College of Medicine

View

Dr. Nerea Lopetegui-Lia

Breast Oncology · OSUMC

View

Dr. Allison Kurian

Breast Oncology · SU

View

Dr. Minhtri Nguyen

Breast Oncology · Advisor

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Patient-reported Outcomes After Routine Treatment of In Situ/Atypical Lesions: The PORTAL Study.

    Jul 27, 2025DOI: 10.1245/s10434-025-17915-4Journal ArticleASO

    Written by: Shoshana M RosenbergChristel RushingKristin L SchreiberKerri-Anne CrowellIsabelle BedrosianKevin S HughesThomas LynchDesiree BasilaDeborah CollyarElizabeth S FrankSonja DaraiConor LanahanJeffrey R MarksJennifer K PlichtaTerry HyslopAlastair M ThompsonAnn H PartridgeE Shelley Hwang

    Find these authors on Roon

    JP

    Dr. Jennifer Plichta

    Breast Surgical Onc · Duke University

    AP

    Dr. Ann Partridge

    Breast Oncology · Dana-Farber Cancer Institute

    Summary

    BACKGROUND: Guideline concordant care (GCC) for ductal carcinoma in situ (DCIS) includes some combination of surgery, radiation, and/or endocrine treatment. Active monitoring (AM) is a common approach for high-risk breast histologies (e.g., atypical ductal hyperplasia [ADH] lobular intraepithelial neoplasias [LIN]) and has been proposed as an alternative to GCC for some low-risk DCIS. We compared patient-reported outcomes in women with DCIS who received GCC with those with other high-risk breast histologies in an active monitoring-proxy group (AM-P).METHODS: Women diagnosed with DCIS (GCC) or ADH/LIN (AM-P) from 2012 to 2017 at four cancer centers were surveyed regarding surgical-area pain, severity, and burden, generalized pain, anxiety, depression, and quality of life (QOL). The primary comparison was GCC versus AM-P. Multivariable logistic regression was used to model odds of reporting surgical-area pain. Multivariable marginal zero-inflated negative binomial models estimated mean scores and differences by group.RESULTS: A total of 912 women completed the survey (GCC, n = 538; AM-P, n = 374). At a median of 45.4 months following diagnosis, the AM-P group had lower odds of pain in the past month (0.35, 95% CI 0.25-0.49) and clinically significant pain (0.43, 95% CI 0.28-0.68). Adjusted mean pain severity index, surgical area sensory disturbance, pain-related cognitive/emotional impact scores were lower in the AM-P versus GCC group. Generalized pain, QOL, anxiety, and depressive symptoms were similar between groups.CONCLUSIONS: Women with DCIS treated with GCC experienced more breast/chest wall pain than women in the AM-P group, although QOL was similar. Understanding these trade-offs can inform surgical de-escalation for high-risk lesions, including low-risk DCIS.
    APDr. Ann Partridge

    Dr. Ann Partridge

    Medical Oncology · Breast Oncology
    Dana-Farber Cancer Institute
    annp